GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Werewolf Therapeutics Inc (NAS:HOWL) » Definitions » PB Ratio

Werewolf Therapeutics (Werewolf Therapeutics) PB Ratio : 2.13 (As of May. 03, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Werewolf Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-03), Werewolf Therapeutics's share price is $6.07. Werewolf Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $2.85. Hence, Werewolf Therapeutics's PB Ratio of today is 2.13.

The historical rank and industry rank for Werewolf Therapeutics's PB Ratio or its related term are showing as below:

HOWL' s PB Ratio Range Over the Past 10 Years
Min: 0.41   Med: 0.92   Max: 2.59
Current: 2.13

During the past 5 years, Werewolf Therapeutics's highest PB Ratio was 2.59. The lowest was 0.41. And the median was 0.92.

HOWL's PB Ratio is ranked better than
56.4% of 1312 companies
in the Biotechnology industry
Industry Median: 2.48 vs HOWL: 2.13

During the past 12 months, Werewolf Therapeutics's average Book Value Per Share Growth Rate was -26.80% per year.

Back to Basics: PB Ratio


Werewolf Therapeutics PB Ratio Historical Data

The historical data trend for Werewolf Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Werewolf Therapeutics PB Ratio Chart

Werewolf Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
- - 2.13 0.53 1.36

Werewolf Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 0.76 0.92 0.68 1.36

Competitive Comparison of Werewolf Therapeutics's PB Ratio

For the Biotechnology subindustry, Werewolf Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Werewolf Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Werewolf Therapeutics's PB Ratio falls into.



Werewolf Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Werewolf Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=6.07/2.848
=2.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Werewolf Therapeutics  (NAS:HOWL) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Werewolf Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Werewolf Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Werewolf Therapeutics (Werewolf Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
Executives
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Luke Evnin director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Meeta Chatterjee director C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michael A. Sherman director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Chulani Karunatilake officer: Chief Technology Officer 1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Reid Leonard officer: Chief Operating Officer 1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mpm Oncology Innovations Fund Lp 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Longwood Fund Iii Gp, Llc 10 percent owner 800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199
Derek Dirocco director 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Moshe Arkin 10 percent owner 6 HACHOSHLIM ST., HERZELIA L3 4672406
Alon Lazarus director, 10 percent owner C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Daniel J Hicklin director, 10 percent owner, officer: See Remarks
Sphera Funds Management Ltd. 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Management Lp 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Gp Ltd. 10 percent owner 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520

Werewolf Therapeutics (Werewolf Therapeutics) Headlines

From GuruFocus

Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference

By Stock market mentor Stock market mentor 02-07-2023